This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

Health care executives continue to reimagine and reshape their organizations. Their ideas were developing in real time during ...

A major conference that took place earlier this month is set to return to San Francisco next year, according to SF Mayor Daniel Lurie’s office. The J.P. Morgan ...

The desire of digital health companies to scale through mergers and acquisitions or partnerships was one of the most ...

Healthcare leaders shared insights on various topics, including industry challenges, a new administration and growing their ...

What does Trump's decision to leave the WHO mean for public health? And should U.S. companies be intimidated by Chinese drug ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

Kyverna Therapeutics, Inc., a leading biotechnology company focusing on autoimmune diseases, revealed its strategic priorities for the year 2025 and anticipated milestones in a recent press release on ...

Cautious Optimism for Deal Making. The general consensus is that we will likely see an increase in M&A and capital market transactions in the ...

Managers Felise Agranoff and Larry Lee have free range to select the top ideas from across J.P. Morgan's growth equity platform, though they ensure the resulting portfolio doesn't fall too far out ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...